Experimental for Duchenne's Muscular Dystrophy (DMD)

Phase-Based Progress Estimates
Nationwide Children's Hospital, Columbus, OH
Duchenne's Muscular Dystrophy (DMD)+2 More
Prednisolone - Drug
< 18
What conditions do you have?

Study Summary

The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose.

Eligible Conditions

  • Duchenne's Muscular Dystrophy (DMD)

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Duchenne's Muscular Dystrophy (DMD)

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Baseline visit to 24 month visit

Month 24
Language (expressive and receptive), Social and Fine Motor skills at 24 months as assessed by the Bayley-4 Scales of Infant and Toddler Development
Linear growth
The change from baseline to 24 months for the Gross Motor Scaled Score.

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Duchenne's Muscular Dystrophy (DMD)

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

26 Total Participants · 1 Treatment Group

Primary Treatment: Experimental · No Placebo Group · Phase 4

Experimental Group · 1 Intervention: Prednisolone · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline visit to 24 month visit
Closest Location: Nationwide Children's Hospital · Columbus, OH
Photo of Columbus  1Photo of Columbus  2Photo of Columbus  3
2007First Recorded Clinical Trial
25 TrialsResearching Duchenne's Muscular Dystrophy (DMD)
491 CompletedClinical Trials

Eligibility Criteria

Age < 18 · Male Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have weakness consistent with Duchenne muscular dystrophy on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.